Study aim: Determining the effect of vaginal estrogen and evening primrose pill in improving the observation of transformation zone in unsatisfactory colposcopy Design: A parallel-group, single-blind, randomized, phase 3 clinical trial on 134 patients. Settings and conduct: This study will be conducted in Arash Hospital. Patients with unsatisfactory colposcopy are divided into two groups. In the first group: daily conjugated estrogen vaginal cream daily for 3 consecutive weeks vaginally and in The second group: the use of evening primrose tablets in a dose of 1000 mg for 3 consecutive weeks is administered vaginally, after 4 weeks colposcopy is performed again. Participants/Inclusion and exclusion criteria: Exclusion criteria: Cervical structural anomalies such as history of cervical insufficiency, Müllerian anomaly and history of conization Having contraindications or sensitivity to evening primrose or estradiol Cancer in the patient or a history of breast or ovarian cancer in the family History of smoking Active vaginal bleeding or pregnancy Post-menopausal women with an inflammatory pap smear or persistent vaginal discharge Taking aspirin or Flavix History of cardiovascular diseases and thromboembolism, sexually transmitted diseases, digestive diseases and neurological diseases, hypertension and coagulopathy, liver disease. Inclusion criteria: Women who are candidates for colposcopy and have an unsatisfactory colposcopy Intervention groups: Intervention groups1: Daily conjugated estrogen vaginal cream (one applicator) vaginally for 3 consecutive weeks Intervention group2: Taking evening primrose tablets (manufactured by Iran's Barij Essential Oil Company) in a dose of 1000 mg vaginally for 3 consecutive weeks. Main outcome variables: Satisfactoryness of colposcopy